Addendum to previous post (needed to include the per annum tag for relevant lines of the model)
The Finacial Model (after Year 2)
Target Population 750,000,000
Target rate @ 10% 75,000,000 Per annum
Margin on each test A$0.75
SBN revenue (membrane only) A56,250,000 Per annum
50% model discount A28,125,000 applied Per annum
SBN EBITDA A28,125,000 Per annum
Business multiple X20 (conservative for Biotech Cos) X10
Market Capitalisation A281,250,000
Number of shares (undiluted) 750,000,000
SP A$0.375
This model has a 50% dicount applied and ignores any potential revenue generated from the 15% equity which would include full retail price margins on the total product including the membrane.
SBN Price at posting:
0.9¢ Sentiment: ST Buy Disclosure: Held
